Early changes in [18F]FLT uptake after chemotherapy: An experimental study

European Journal of Nuclear Medicine

Volumn 29, Issue 11, 2002, Pages 1462-1469

  Dittmann, Helmut ^a,b   Dohmen, Bernhard ^a,b   Kehlbach, Rainer ^a,b   Bartusek, Gabi ^a,b   Pritzkow, Maren ^a,b   Sarbia, Mario ^a,b   Bares, Roland ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Fluorothymidine; Positron emission tomography; Salvage pathway; Treatment response

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; CISPLATIN; FLUORODEOXYGLUCOSE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER CHEMOTHERAPY; CELL COUNT; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DNA SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; POSITRON EMISSION TOMOGRAPHY; TISSUE CULTURE; TUMOR CELL; ARTIFACT; CELL CULTURE; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; ESOPHAGUS TUMOR; EVALUATION; METABOLISM; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STATISTICS; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; ARTIFACTS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; HUMANS; METHOTREXATE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS; TUMOR CELLS, CULTURED;

EID: 0036032285     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0925-z     Document Type: Article

References (34)

1. Flexner C, van der Horst C, Jacobson MA, et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 1994; 170:1394-1403.
2. Kong XB, Zhu QY, Vidal PM, Watanabe KA, Polsky B, Armstrong D, Ostrander M, Lang SA, Muchmore E, Chou TC. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinet-ics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythy-midine. Antimicrob Agents Chemother 1992; 36:808-818.
3. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988; 263:8350-8358.
4. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336.
5. 18F-FLT. J Nucl Med 2000; 41(Suppl):74P.
6. Damiens E. Molecular events that regulate cell proliferation: An approach for the development of new anticancer drugs. Prog Cell Cycle Res 2000; 4:219-233.
7. Kinsella AR, Smith D, Pickard M. Resistance to chemotherapeutic antimetabolites: A function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 1997; 75:935-945.
8. 18F]FLT; portrait of a proliferation marker. Eur J Nucl Med 2002; 29:165-169.
9. Haberkorn U, Altmann A, Kamencic H, Morr I, Traut U, Henze M, Shiming J, Metz J, Kinscherf R. Glucose transport and apoptosis after gene therapy with HSV thymidine kinase. Eur J Nucl Med 2001; 28:1690-1696.
10. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ; Spencer S, Asbell SO, Graham MV, Leichman LL. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281:1623-1627.
11. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982; 42:450-456.
12. Pil PM, Lippard SJ. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin. Science 1992; 256:234-237.
13. Huang P, Plunkett W. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event. Cancer Chemother Pharmacol 1995; 36:181-188.
14. Sarbia M, Bosing N, Hildebrandt B, Koldovsky P, Gerharz CD, Gabbert HE. Characterization of two newly established cell lines derived from squamous cell carcinomas of the esophagus. Anticancer Res 1997; 17:2185-2192.
15. Yung WK. In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg Rev 1989; 12:197-203.
16. Blocher A, Kuntzsch M, Wei R, Machulla HJ. Synthesis and labeling of 5′-O-(4,4′-dimethoxytrityl)-2,3′-anhydrothymidine for [F-18]FLT preparation. J Radioanalytical Nucl Chem 2002; 2251:55-58.
17. Braakhuis BJ, van-Dongen G-A, Vermorken JB, Snow GB. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991; 51:211-214.
18. Mirjolet JF, Barberi-Heyob M, Merlin JL, Marchal S, Etienne MC, Milano G, Bey P. Thymidylate synthase expression and activity: Relation to S phase parameters and 5-fluorouracil sensitivity. Br J Cancer 1998; 78:62-68.
19. Tsurusawa M, Niwa M, Katano N, Fujimoto T. Flow cytometric analysis by bromodeoxyuridine/DNA assay of cell cycle perturbation of methotrexate-treated mouse L1210 leukemia cells. Cancer Res 1988; 48:4288-4293.
20. Yamane N, Makino M, Kaibara N. S phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells. Cancer 1999; 85:309-317.
21. Mori H, Nakayama K, Ishida R, Ito S, Nagai H, Koda A. Irreversible cytotoxic effect of a novel lowly immunosuppressive antitumor fluorouridine derivative, UK-21. Anticancer Drugs 1997; 8:482-488.
22. Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv Enzyme Regul 1995; 35:69-89.
23. Grierson JR, Vesselle H, Hofstrand P, Chin L, Rasey JS. Comparative uptake and cell cycle measurements with [F-18]-FLT vs [H-3]thymidine in mammalian tumor cells. J Nucl Med 1998 39 (Suppl):229P-230P.
24. Rasey JS, Grierson JR, Wiens LW, Kolb PE. Uptake of labeled FLT correlates with thymidine kinase (TK1) activity in human tumor cells. J Nucl Med 2000; 41(Suppl):36P.
25. Lipson KE, Baserga R. Transcriptional activity of the human thymidine kinase gene determined by a method using the polymerase chain reaction and an intron-specific probe. Proc Natl Acad Sci USA 1989; 86:9774-9777.
26. Demarcq C, Bastian G, Remvikos Y. BrdUrd/DNA flow cytometry analysis demonstrates cis-diamminedichloroplatinum (II)-induced multiple cell-cycle modifications on human lung carcinoma cells. Cytometry 1992; 13:416-422.
27. Higashi K, Clavo AC, Wahl RL. In vitro assessment of 2-fluoro-2-deoxy-D-glucose,L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy. J Nucl Med 1993; 34:773-779.
28. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, Zheng M, Lewellen B, Lewellen TK, Grierson JR, Krohn KA. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39:1757-1762.
29. Look KY, Moore DH, Sutton GP, Prajda N, Abonyi M, Weber G. Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. Anticancer Res 1997; 17:2353-2356.
30. Weber G, Nagai M, Natsumeda Y, et al. Regulation of de novo and salvage pathways in chemotherapy. Adv Enzyme Regul 1991; 31:45-67.
31. Romain S, Spyratos F, Descotes F, Daver A, Rostaing-Puissant B, Bougnoux P, Colonna M, Bolla M, Martin PM. Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: A retrospective multicenter study. Int J Cancer 2000; 87:860-868.
32. Yasuda C, Kato M, Kuroda D, Ohyanagi H. Experimental studies on potentiation of the antitumor activity of 5-fluoro-uracil with 3′-azido-3′-deoxythymidine for the gastric cancer cell line MKN28 in vivo. Jpn J Cancer Res 1997; 88:97-102.
33. Marumo K, Oya M, Murai M. Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma. Int J Urol 1997; 4:163-168.
34. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 2000; 60:6075-6079.